1. Home
  2. MRCC vs IPSC Comparison

MRCC vs IPSC Comparison

Compare MRCC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

N/A

Current Price

$6.33

Market Cap

151.2M

Sector

Finance

ML Signal

N/A

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

N/A

Current Price

$0.67

Market Cap

49.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MRCC
IPSC
Founded
2011
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.2M
49.8M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
MRCC
IPSC
Price
$6.33
$0.67
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$8.00
$3.00
AVG Volume (30 Days)
93.3K
840.4K
Earning Date
11-05-2025
11-13-2025
Dividend Yield
15.77%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,742,000.00
$113,337,000.00
Revenue This Year
N/A
$1,590.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4122.69
52 Week Low
$5.86
$0.34
52 Week High
$8.85
$1.26

Technical Indicators

Market Signals
Indicator
MRCC
IPSC
Relative Strength Index (RSI) 39.87 70.42
Support Level $6.65 $0.54
Resistance Level $6.80 $0.62
Average True Range (ATR) 0.15 0.04
MACD -0.00 0.01
Stochastic Oscillator 17.29 89.83

Price Performance

Historical Comparison
MRCC
IPSC

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Share on Social Networks: